Analyst Reco. Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
4.08 ^USD	+3.29%		-5.12%	+9.09%

22/04	Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	CI
21/03	Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Raises Fate Therapeutics Price Target to $7 From $3, Maintains Equalweight Rating	27/02	MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $7 From $6, Maintains Market Perform Rating	27/02	MT
Barclays Adjusts Price Target on Fate Therapeutics to $10 From $6, Maintains Overweight Rating	27/02	MT
Wedbush Raises Fate Therapeutics' Price Target to $7 From $3, Keeps Neutral Rating	27/02	MT
Mizuho Lowers Price Target on Fate Therapeutics to $8 From $12, Maintains Buy Rating	20/11	MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $3 From $5, Maintains Equalweight Rating	13/11	MT
Wells Fargo Trims Price Target on Fate Therapeutics to $5 From $6, Maintains Equalweight Rating	09/11	MT
Wedbush Lowers Fate Therapeutics' Price Target to $3 From $6, Maintains Neutral Rating	09/11	MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $5 From $8, Keeps Equalweight Rating	10/23/10	MT
Barclays Adjusts Fate Therapeutics Price Target to $6 From $12, Maintains Overweight Rating	10/23/10	MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $5.40 From $6, Maintains Market Perform Rating	09/23/09	MT
Wedbush Trims Fate Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating	09/23/09	MT
Stifel Nicolaus Adjusts Fate Therapeutics Price Target to $5 From $5.30, Maintains Hold Rating	04/23/04	MT
Cantor Fitzgerald Adjusts Price Target on Fate Therapeutics to $5 From $8, Maintains Neutral Rating	04/23/04	MT
Wells Fargo Assumes Coverage on Fate Therapeutics With Equal Weight Rating, $6 Price Target	27/23/27	MT
Citigroup Adjusts Fate Therapeutics Price Target to $10 From $9, Maintains Buy Rating	02/23/02	MT
HC Wainwright Downgrades Fate Therapeutics to Neutral From Buy, Adjusts Price Target to $7 From $115	24/23/24	MT
Goldman Sachs Adjusts Price Target on Fate Therapeutics to $4 From $10, Maintains Sell Rating	09/23/09	MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $8 From $35, Maintains Equalweight Rating	06/23/06	MT
EF Hutton Adjusts Fate Therapeutics' Price Target to $10 From $16, Keeps Buy Rating	06/23/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Analyst Reco.

Filters